Compass Pathways (CMPS) announced it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
- PBM, CMPS, ATAI: Psychedelic Biotech Stocks Soar after White House Order for Faster FDA Reviews
- Compass Pathways ‘commends’ White House Executive Order to accelerate research
- Trump Trade: President to sign order on psychedelic used for PTSD
- Trump to sign order on psychedelic used for PTSD, CBS News says